Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dietary sodium Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection

NCT01972334
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
FMT, placebo
Biological
Lead sponsor
MemorialCare Health System
Other
Eligibility
1 Year to 21 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy

NCT01665911
View directory record Official record
Conditions
Caries
Interventions
1.5 mg Sodium Fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk, Non-fluoridated milk, 200 ml
Drug · Other
Lead sponsor
Frank Lippert
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01957150
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 15, 2026, 5:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959
View directory record Official record
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

Trial of Nonpharmacologic Interventions in Elderly (TONE)

NCT00000535
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Vascular Diseases
Interventions
diet, reducing, diet, sodium-restricted
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
60 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1997
U.S. locations
4
States / cities
Baltimore, Maryland • New Brunswick, New Jersey • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated No phase listed Observational

Genetic Mechanisms in Human Hypertension

NCT01456208
View directory record Official record
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 15, 2026, 5:59 PM EDT
Suspended Phase 1 Interventional

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161
View directory record Official record
Conditions
Ovarian Tumors
Interventions
GRN-300, Paclitaxel
Drug
Lead sponsor
Green3Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

NCT01101451
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage I Cervical Cancer AJCC v6 and v7, Stage IA Cervical Cancer AJCC v6 and v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7
Interventions
Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
698
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 433 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis

NCT00589745
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nasal potential difference measurement
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

NCT00131911
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome
Interventions
sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

NCT07332741
View directory record Official record
Conditions
Hypertension, Hypertension (HTN), Obesity & Overweight
Interventions
FIM intervention arm, FIM Usual Care Arm
Combination Product
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Not applicable Interventional

Reliability of Central Venous Pressure Measurements

NCT01116973
View directory record Official record
Conditions
Hemodynamics, Central Venous Pressure
Interventions
PICC
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

Practice-based Trial of Blood Pressure Control in African Americans

NCT01070056
View directory record Official record
Conditions
Hypertension, Physical Activity, Diet, Medication Adherence
Interventions
Therapeutic Lifestyle Changes (MINT-TLC), Usual Care
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults

NCT01566084
View directory record Official record
Conditions
Hypertension
Interventions
Slow sodium tablets, placebo
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
50 Years to 79 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT01935947
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 15, 2026, 5:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
838
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

NCT02877264
View directory record Official record
Conditions
Healthy
Interventions
vapendavir 132 mg capsule, vapendavir 264 mg tablet, vapendavir 24 mg/mL oral suspension
Drug
Lead sponsor
Aviragen Therapeutics
Industry
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04267848
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1150
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge

NCT01336816
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Ariva Silver Wintergreen, Placebo Wintergreen
Other
Lead sponsor
Star Scientific, Inc
Industry
Eligibility
23 Years to 72 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Martinsburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 15, 2026, 5:59 PM EDT